Editorial Comment: Intra-cavernous injection of BOTOX ® (50 and 100 Units) for treatment of vasculogenic erectile dysfunction: Randomized controlled trial

0Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Onabotulinum toxin-A (BTX) is widely used to treat various medical conditions such as striated and smooth muscle disorders. In urologic disorders, the use of BTX has been approved to treat detrusor overactivity (1).

Cite

CITATION STYLE

APA

El-Shaer, W., Ghanem, H., Diab, T., Abo-Taleb, A., Kandeel, W., & de Castro Barros, R. (2022). Editorial Comment: Intra-cavernous injection of BOTOX ® (50 and 100 Units) for treatment of vasculogenic erectile dysfunction: Randomized controlled trial. International Braz J Urol. Brazilian Society of Urology. https://doi.org/10.1590/S1677-5538.IBJU.2022.06.03

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free